These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 16508734)
1. Timing of significant adverse events is essential information during early development of new drugs. Hyodo I Int J Clin Oncol; 2006 Feb; 11(1):69; author reply 69-70. PubMed ID: 16508734 [No Abstract] [Full Text] [Related]
2. The use of capecitabine in cancer: management of the hand foot syndrome. Sudoyo AW Acta Med Indones; 2005; 37(3):174-6. PubMed ID: 16110178 [No Abstract] [Full Text] [Related]
3. A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors. Saeki T; Takashima S; Terashima M; Satoh A; Toi M; Osaki A; Toge T; Ohno S; Nomura N; Fukuyama Y; Koizumi W; Taguchi T Int J Clin Oncol; 2005 Feb; 10(1):51-7. PubMed ID: 15729602 [TBL] [Abstract][Full Text] [Related]
4. [Use of xeloda (capecitabine) in the treatment of cancer patients (review)]. Orel NF Ter Arkh; 2003; 75(10):65-70. PubMed ID: 14669610 [No Abstract] [Full Text] [Related]
5. Capecitabine: have we got the dose right? Midgley R; Kerr DJ Nat Clin Pract Oncol; 2009 Jan; 6(1):17-24. PubMed ID: 18936793 [TBL] [Abstract][Full Text] [Related]
6. Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient. Ratain MJ J Clin Oncol; 2002 Mar; 20(6):1434-5. PubMed ID: 11896086 [No Abstract] [Full Text] [Related]
7. Capecitabine-induced oromandibular dystonia: a case report and literature review. Ngeow JY; Prakash KM; Chowbay B; Quek ST; Choo SP Acta Oncol; 2008; 47(6):1161-5. PubMed ID: 18607849 [No Abstract] [Full Text] [Related]
8. A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies. Gallerani E; Bauer J; Hess D; Boehm S; Droege C; Jeckelmann S; Miani M; Herrmann R; Marsoni S; Sperka S; Sessa C Acta Oncol; 2011 Oct; 50(7):1105-10. PubMed ID: 21184645 [TBL] [Abstract][Full Text] [Related]
15. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. Traina TA; Theodoulou M; Feigin K; Patil S; Tan KL; Edwards C; Dugan U; Norton L; Hudis C J Clin Oncol; 2008 Apr; 26(11):1797-802. PubMed ID: 18398145 [TBL] [Abstract][Full Text] [Related]
16. Capecitabine-induced pancreatitis. Jones KL; Valero V Pharmacotherapy; 2003 Aug; 23(8):1076-8. PubMed ID: 12921254 [TBL] [Abstract][Full Text] [Related]
17. A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis. Jhaveri KD; Flombaum C; Shah M; Latcha S J Oncol Pharm Pract; 2012 Mar; 18(1):140-7. PubMed ID: 22392964 [TBL] [Abstract][Full Text] [Related]
18. Inflammation of actinic keratoses with capecitabine therapy for colon cancer. Serrão VV; Feio AB Eur J Dermatol; 2008; 18(2):200. PubMed ID: 18424393 [No Abstract] [Full Text] [Related]
19. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. Dunst J; Reese T; Sutter T; Zühlke H; Hinke A; Kölling-Schlebusch K; Frings S J Clin Oncol; 2002 Oct; 20(19):3983-91. PubMed ID: 12351595 [TBL] [Abstract][Full Text] [Related]
20. Safety of capecitabine: a review. Mikhail SE; Sun JF; Marshall JL Expert Opin Drug Saf; 2010 Sep; 9(5):831-41. PubMed ID: 20722491 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]